Similarly, inhibiting EZH2 has been reported to enhance the sensitivity of the pan‐PI3K inhibitor copanlisib in lung cancer cells harbouring mutated or amplified PIK3CA when the manuscript was in preparation.60 Here, EZH2 is linked to lung cancer.